Abstract
Background: Hepatocellular carcinoma (HCC) represents the most common malignant liver tumor in humans, which incidence and mortality have increased in Europe and United States in the last years. Most patients are diagnosed at an advanced stage, when it is not amenable to curative therapies, so there is an urgent need for new, more effective therapeutic tools and strategies. The molecular mechanisms of hepatocarinogenesis and HCC progression have been increasingly understood with intense research in recent years.
Methods: The goal of this work is to discuss the different signalling pathways as important potential therapeutic targets. Results: Disruption of pathways known to play roles in HCC, such as Wnt/β-catenin, Hedgehog, RAF/MEK/ERK, tryosine kinase receptor-related pathway, Met-HGF, VEGF/ VEGF and ROR signalling pathways may be seminal for liver oncogenesis. Conclusion: This review reveals that oncogenes, especially microRNAs that are conserved across species and interfere with signalling pathways might be used as promising strategies for halting or reversing the progression of HCC.Keywords: Hepatocellular carcinoma, hepatocarcinogenesis, genomics, signalling pathway, drug targets, microRNA.
Current Pharmaceutical Design
Title:Targeting Signalling Pathways in Hepatocellular Carcinoma
Volume: 23 Issue: 1
Author(s): Kaja Blagotinsek and Damjana Rozman
Affiliation:
Keywords: Hepatocellular carcinoma, hepatocarcinogenesis, genomics, signalling pathway, drug targets, microRNA.
Abstract: Background: Hepatocellular carcinoma (HCC) represents the most common malignant liver tumor in humans, which incidence and mortality have increased in Europe and United States in the last years. Most patients are diagnosed at an advanced stage, when it is not amenable to curative therapies, so there is an urgent need for new, more effective therapeutic tools and strategies. The molecular mechanisms of hepatocarinogenesis and HCC progression have been increasingly understood with intense research in recent years.
Methods: The goal of this work is to discuss the different signalling pathways as important potential therapeutic targets. Results: Disruption of pathways known to play roles in HCC, such as Wnt/β-catenin, Hedgehog, RAF/MEK/ERK, tryosine kinase receptor-related pathway, Met-HGF, VEGF/ VEGF and ROR signalling pathways may be seminal for liver oncogenesis. Conclusion: This review reveals that oncogenes, especially microRNAs that are conserved across species and interfere with signalling pathways might be used as promising strategies for halting or reversing the progression of HCC.Export Options
About this article
Cite this article as:
Blagotinsek Kaja and Rozman Damjana, Targeting Signalling Pathways in Hepatocellular Carcinoma, Current Pharmaceutical Design 2017; 23 (1) . https://dx.doi.org/10.2174/1381612822666161006160005
DOI https://dx.doi.org/10.2174/1381612822666161006160005 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Perspective on Nanoparticle Technology for Biomedical Use
Current Pharmaceutical Design Breast Cancer, a Stem Cell Disease
Current Stem Cell Research & Therapy Liver-Directed Regional Therapy in the Multi-Disciplinary Management of Hepatocellular Cancer
Current Cancer Therapy Reviews Tetraspanins - Gateways for Infection
Infectious Disorders - Drug Targets Ring Opening of Tetrazole via Unusual Vilsmeir-Haack Reaction Forming Novel Triazenes
Letters in Organic Chemistry Mapping the High Throughput SEREX Technology Screening for Novel Tumor Antigens
Combinatorial Chemistry & High Throughput Screening Tumor Stroma as a Target in Cancer
Current Cancer Drug Targets Biomedical Applications of Gold Nanoparticles
Current Topics in Medicinal Chemistry Chronic Inflammatory-Modulating Potential of <i>Cassia auriculata</i> with Proinflammatory Cytokine IL-1beta and Its Anticancer Effect on Lung Cancer Cell Line
Anti-Cancer Agents in Medicinal Chemistry Targeting the Nucleus: An Overview of Auger-Electron Radionuclide Therapy
Current Drug Discovery Technologies Combined Treatment with PPAR-γ Agonists in Pancreatic Cancer: A Glimmer of Hope for Cancer Therapy?
Current Cancer Drug Targets Targeted Therapies in the Treatment of Advanced Renal Cell Carcinoma
Recent Patents on Anti-Cancer Drug Discovery Threat Posed by Persistent Organochlorine Pesticides and their Mobility in the Environment
Current Organic Chemistry Biomarkers and Multiple Drug Resistance in Breast Cancer
Current Cancer Drug Targets Monoclonal Antibody Therapy in Haematological Malignancies
Current Clinical Pharmacology Association of p53 with Bid Induces Cell Death in Response to Etoposide Treatment in Hepatocellular Carcinoma
Current Cancer Drug Targets Synthesis and <i>In Silico</i> Studies of C-4 Substituted Coumarin Analogues as Anticancer Agents
Current Computer-Aided Drug Design Heat Shock Protein 90 – a Potential Target in the Treatment of Human Acute Myelogenous Leukemia
Current Cancer Drug Targets Synthesis of New α-Amino Phosphonates Containing 3-Amino-4(3H) Quinazolinone Moiety as Anticancer and Antimicrobial Agents: DFT, NBO, and Vibrational Studies
Current Organic Synthesis Radiolabeled Peptides in Imaging and Therapy: Basic and Clinical Perspectives
Current Medicinal Chemistry